The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Health Care Costs

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Health Care Costs


Psychiatry related information on Health Care Costs


High impact information on Health Care Costs

  • RESULTS--Assuming transmission rates are reduced from 25.5% to 8.3% as found in the ACTG 076 trial, treatment costs of $104,502 for 100 HIV-positive pregnant women and their newborns are offset by the reduction of $1,701,333 associated with fewer cases of pediatric HIV infection for a net savings of $1,596,831 [1].
  • Therefore, despite both the high cost of carrier testing and the relative infrequency of CF conceptions in the general population, the averted medical-care cost resulting from choices freely made are estimated to offset approximately 74%-78% of the costs of a screening program [11].
  • The average treatment costs were 25% higher in arm C as compared with arms A and B. CONCLUSION: Gemcitabine plus cisplatin and paclitaxel plus gemcitabine do not increase overall survival in patients with advanced NSCLC as compared with paclitaxel plus cisplatin [12].
  • CONCLUSION: The short administration schedule for the treatment of children with WT is no less effective than the long administration schedule and can be administered at a substantially lower total treatment cost [13].
  • RESULTS: The mean total annual direct medical care cost in 2001 for a patient with RA was 9,519 US dollars [14].

Chemical compound and disease context of Health Care Costs


Biological context of Health Care Costs

  • In addition, we have also found that delayed addition of G-CSF during the mobilization of PBSC was feasible and resulted in excellent CD34+ cell counts and engraftments, and reduced treatment costs [20].

Anatomical context of Health Care Costs


Associations of Health Care Costs with chemical compounds


Gene context of Health Care Costs

  • CONCLUSIONS: Combined pharmacogenetic testing for CYP2D6 and CYP2C19 identifies patients with low risk for side effects in amitriptyline therapy and could possibly be used to individualize antidepressive regimens and reduce treatment cost [28].
  • We describe the impact of the genetic analysis for MODY 2 on diabetes management and treatment costs in a five-year-old girl [29].
  • Concurrent treatment costs were identified through chart review for days in isolation, antimicrobial therapy, and MRSA screening tests [30].
  • BACKGROUND: Infections with methicillin-resistant Staphylococcus species (MRSS) are associated with higher treatment costs than infections with methicillin-sensitive Staphylococcus species in the United States--partly because of an increased length of hospital stay (LOS) [31].
  • The reduction of treatment costs by reducing the total G-CSF dose may be important in future treatment with this hematopoietic growth factor [32].

Analytical, diagnostic and therapeutic context of Health Care Costs


  1. Economic impact of treatment of HIV-positive pregnant women and their newborns with zidovudine. Implications for HIV screening. Mauskopf, J.A., Paul, J.E., Wichman, D.S., White, A.D., Tilson, H.H. JAMA (1996) [Pubmed]
  2. Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis. Singh, G., Miller, J.D., Huse, D.M., Pettitt, D., D'Agostino, R.B., Russell, M.W. J. Rheumatol. (2003) [Pubmed]
  3. Cerivastatin versus branded pravastatin in the treatment of primary hypercholesterolemia in primary care practice in Canada: a one-year, open-label, randomized, comparative study of efficacy, safety, and cost-effectiveness. McPherson, R., Hanna, K., Agro, A., Braeken, A. Clinical therapeutics. (2001) [Pubmed]
  4. Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer. Simons, W.R., Jones, D., Buzdar, A. Clinical therapeutics. (2003) [Pubmed]
  5. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations. Collins, A.J. Nephrol. Dial. Transplant. (2003) [Pubmed]
  6. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. Brevetti, G., Perna, S., Sabbà, C., Rossini, A., Scotto di Uccio, V., Berardi, E., Godi, L. Eur. Heart J. (1992) [Pubmed]
  7. Clinical and economic impact of newer versus older antipsychotic medications in a community mental health center. Galvin, P.M., Knezek, L.D., Rush, A.J., Toprac, M.G., Johnson, B. Clinical therapeutics. (1999) [Pubmed]
  8. The mortality, morbidity, and economic costs of alcohol abuse in New Hampshire. Gorsky, R.D., Schwartz, E., Dennis, D. Preventive medicine. (1988) [Pubmed]
  9. Impact of risperidone on the use of mental health care resources. Viale, G., Mechling, L., Maislin, G., Durkin, M., Engelhart, L., Lawrence, B.J. Psychiatric services (Washington, D.C.) (1997) [Pubmed]
  10. Cost-effectiveness analysis of a brief intervention delivered to problem drinkers presenting at an inner-city hospital emergency department. Kunz, F.M., French, M.T., Bazargan-Hejazi, S. J. Stud. Alcohol (2004) [Pubmed]
  11. Prenatal screening for cystic fibrosis carriers: an economic evaluation. Rowley, P.T., Loader, S., Kaplan, R.M. Am. J. Hum. Genet. (1998) [Pubmed]
  12. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. Smit, E.F., van Meerbeeck, J.P., Lianes, P., Debruyne, C., Legrand, C., Schramel, F., Smit, H., Gaafar, R., Biesma, B., Manegold, C., Neymark, N., Giaccone, G. J. Clin. Oncol. (2003) [Pubmed]
  13. Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. Green, D.M., Breslow, N.E., Beckwith, J.B., Finklestein, J.Z., Grundy, P., Thomas, P.R., Kim, T., Shochat, S., Haase, G., Ritchey, M., Kelalis, P., D'Angio, G.J. J. Clin. Oncol. (1998) [Pubmed]
  14. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Michaud, K., Messer, J., Choi, H.K., Wolfe, F. Arthritis Rheum. (2003) [Pubmed]
  15. Cost of oral antibiotic therapy. Nightingale, C.H., Quintiliani, R. Pharmacotherapy (1997) [Pubmed]
  16. Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections. Young, M., Plosker, G.L. PharmacoEconomics. (2001) [Pubmed]
  17. Outcomes of cefazolin versus ceftriaxone therapy in treating lower respiratory tract infections in adults. Thompson, D., Huse, D.M., Oster, G. The Annals of pharmacotherapy. (1992) [Pubmed]
  18. Acute uncomplicated UTI and E. coli resistance: implications for first-line empirical antibiotic therapy. Perfetto, E.M., Keating, K., Merchant, S., Nichols, B.R. Journal of managed care pharmacy : JMCP. (2004) [Pubmed]
  19. The mounting medical care cost for adult AIDS patients at the Faculty of Medicine, Siriraj Hospital: consideration for management. Suwanagool, S., Ratanasuwan, W., Techasathit, W. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. (1997) [Pubmed]
  20. A novel high-dose chemotherapy protocol with autologous hematopoietic rescue in patients with metastatic breast cancer or recurrent non-Hodgkin's lymphoma. Fontelonga, A., Kelly, A.J., MacKintosh, F.R., Hall, S., Monroe, P., Wilson, G.S., Shaft, D., Ruthven, A., Ascensao, J.L. Bone Marrow Transplant. (1997) [Pubmed]
  21. Costs of peripheral blood progenitor cell transplantation using whole blood mobilised by filgrastim as compared with autologous bone marrow transplantation in non-Hodgkin's lymphoma. Uyl-de Groot, C.A., Ossenkoppele, G.J., Buijt, I., Huijgens, P.C. PharmacoEconomics. (1999) [Pubmed]
  22. Socio-economic impact of chronic venous insufficiency. An underestimated public health problem. Van den Oever, R., Hepp, B., Debbaut, B., Simon, I. International angiology : a journal of the International Union of Angiology. (1998) [Pubmed]
  23. The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins? Grover, S.A., Ho, V., Lavoie, F., Coupal, L., Zowall, H., Pilote, L. Arch. Intern. Med. (2003) [Pubmed]
  24. Higher medical care costs accompany impaired fasting glucose. Nichols, G.A., Brown, J.B. Diabetes Care (2005) [Pubmed]
  25. Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study. Herman, W.H., Alexander, C.M., Cook, J.R., Boccuzzi, S.J., Musliner, T.A., Pedersen, T.R., Kjekshus, J., Pyörälä, K. Diabetes Care (1999) [Pubmed]
  26. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Eastman, R.C., Javitt, J.C., Herman, W.H., Dasbach, E.J., Copley-Merriman, C., Maier, W., Dong, F., Manninen, D., Zbrozek, A.S., Kotsanos, J., Garfield, S.A., Harris, M. Diabetes Care (1997) [Pubmed]
  27. A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly. Fløgstad, A.K., Halse, J., Grass, P., Abisch, E., Djøseland, O., Kutz, K., Bodd, E., Jervell, J. J. Clin. Endocrinol. Metab. (1994) [Pubmed]
  28. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Steimer, W., Zöpf, K., von Amelunxen, S., Pfeiffer, H., Bachofer, J., Popp, J., Messner, B., Kissling, W., Leucht, S. Clin. Chem. (2005) [Pubmed]
  29. Genetic testing for glucokinase mutations in clinically selected patients with MODY: a worthwhile investment. Schnyder, S., Mullis, P.E., Ellard, S., Hattersley, A.T., Flück, C.E. Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology. (2005) [Pubmed]
  30. The economic impact of methicillin-resistant Staphylococcus aureus in Canadian hospitals. Kim, T., Oh, P.I., Simor, A.E. Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America. (2001) [Pubmed]
  31. Cost analysis of switching from i.v. vancomycin to p.o. linezolid for the management of methicillin-resistant Staphylococcus species. McCollum, M., Rhew, D.C., Parodi, S. Clinical therapeutics. (2003) [Pubmed]
  32. Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia. Hofmann, W.K., Seipelt, G., Langenhan, S., Reutzel, R., Schott, D., Schoeffski, O., Illiger, H.J., Hartmann, F., Balleisen, L., Franke, A., Fiedler, F., Huber, C., Rasche, H., Bergmann, L., Ganser, A., Pott, C., Pasold, R., Rudolph, C., Ottmann, O.G., Gökbuget, N., Hoelzer, D. Ann. Hematol. (2002) [Pubmed]
  33. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy. Zagonel, V., Babare, R., Merola, M.C., Talamini, R., Lazzarini, R., Tirelli, U., Carbone, A., Monfardini, S. Ann. Oncol. (1994) [Pubmed]
  34. Helicobacter pylori test & treat strategy for dyspepsia: a qualitative study exploring the barriers and how to overcome them. McNulty, C., Freeman, E., Delaney, B. Family practice. (2006) [Pubmed]
  35. Immunosuppressive therapy with microemulsion cyclosporine A shortens the hospitalization of pediatric liver transplant recipients. Arumugam, R., Soriano, H.E., Scheimann, A.O., Reid, B.S., Gopalakrishna, G.S., Barakat, O., Ozaki, C.F., Wood, P.R. Clinical transplantation. (1998) [Pubmed]
  36. Treatment costs and patient outcomes with use of risperidone in a public mental health setting. Schiller, M.J., Shumway, M., Hargreaves, W.A. Psychiatric services (Washington, D.C.) (1999) [Pubmed]
WikiGenes - Universities